| Acurx Pharmaceuticals is a clinical stage biopharmaceutical company developing a class of antibiotics for infections caused by bacteria. Co.'s research and development pipeline includes clinical stage and early stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile, Enterococcus (including vancomycin-resistant strains), Staphylococcus (including methicillin-resistant strains), and Streptococcus (including antibiotic resistant strains). Co.'s primary antibiotic candidate, ibezapolstat, has a mechanism of action that targets the DNA polymerase IIIC enzyme, an unexploited scientific target. We show 7 historical shares outstanding datapoints in our ACXP shares outstanding history coverage, used to compute ACXP market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACXP market cap history over the course of time is important for investors
interested in comparing ACXP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACXP versus a peer is one thing; comparing
ACXP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACXP can fluctuate over the course of history.
With this page we aim to empower investors researching ACXP by allowing them to research the ACXP market cap history.